AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 January 2022 - 08:05AM
Business Wire
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell
immunotherapy company, today announced that Diana Brainard, M.D.,
Chief Executive Officer, will present at the 40th Annual J.P.
Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30
p.m. ET.
An audio-only webcast of the presentation will be available on
the Investors & Press section of the AlloVir website at
https://ir.allovir.com/events-and-presentations. An archived replay
of the presentation will be available for 30 days following the
presentation.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter or LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005457/en/
Media and Investor Contact: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Feb 2024 to Mar 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Mar 2023 to Mar 2024